Biology subjects

Khalife, J.

Publications and source records attributed to Khalife, J..

5 recordsLinked to original sources

bioRxiv2023

IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexes

In diffuse large B-cell lymphoma (DLBCL), the transcription factor IRF8 is the target of a series of potentially oncogenic events, including, chromosomal translocation, focal amplification, and super-enhancer perturbations. IRF8 is also frequently mutant in DLBCL, but how these variants contribute to lymphomagenesis is unknown. We modeled IRF8 mutations in DLBCL and found that they did not meaningfully impact cell fitness. Instead, IRF8 mutants, mapping either to the DNA-binding domain (DBD) or c-terminal tail, displayed diminished transcription activity towards CIITA, a direct IRF8 target. In primary DLBCL, IRF8 mutations were mutually exclusive with mutations in genes involved in antigen presentation. Concordantly, expression of IRF8 mutants in murine B cell lymphomas uniformly suppressed CD4, but not CD8, activation elicited by antigen presentation. Unexpectedly, IRF8 mutation did not modify MHC CII expression on the cell surface, rather it downmodulated CD74 and HLA- DM, intracellular regulators of antigen peptide processing/loading in the MHC CII complex. These changes were functionally relevant as, in comparison to IRF8 WT, mice harboring IRF8 mutant lymphomas displayed a significantly higher tumor burden, in association with a substantial remodeling of the tumor microenvironment (TME), typified by depletion of CD4, CD8, Th1 and NK cells, and increase in T-regs and Tfh cells. Importantly, the clinical and immune phenotypes of IRF8-mutant lymphomas were rescued in vivo by ectopic expression of CD74. Deconvolution of bulk RNAseq data from primary human DLBCL recapitulated part of the immune remodeling detected in mice and pointed to depletion of dendritic cells as another feature of IRF8 mutant TME. We concluded that IRF8 mutations contribute to DLBCL biology by facilitating immune escape.

cancer biology↗

bioRxiv2023

Characterization of the Plasmodium berghei regulatory AAA-ATPase subunit Rpt3 as an activator of Protein Phosphatase 1: direct and indirect evidence

The 26S proteasome is the main proteolytic machine involved in protein degradation, thus contributing to homeostasis or stress response of eukaryotic cells. This macromolecular complex, consisting of a 20S core particle assembled with one or two 19S regulatory particles, is highly regulated by phosphorylation. Here we describe the Plasmodium berghei proteasome AAA-ATPase regulatory subunit Rpt3 and show that it binds to protein phosphatase 1, the major parasite phosphatase. In addition, PbRpt3 regulates the activity of the phosphatase both in vitro and in a heterologous model of Xenopus oocytes. Using mutagenesis approaches, we observed that the RVXF motifs of PbRpt3 are involved in this binding and activity. Further use of Xenopus oocyte model and mutagenesis based on the 3D model that we established revealed that the binding capacity of PbRpt3 to ATP may also contribute to its phosphatase-regulating activity. In the parasite, reverse genetic studies suggested an essential role for PbRpt3 since no viable knock-out line could be obtained. Additionally, immunoprecipitation assays followed by mass spectrometry analyses using transgenic PbRpt3-tagged parasites not only confirmed that PbRpt3 belongs to the 19S regulatory particle of the proteasome, but also revealed potential interaction with proteins already shown to play a role in the phospholipid membrane dynamics.

microbiology↗

bioRxiv2023

Characterization of GEXP15 as a potential regulator of Protein Phosphatase 1 and partner of ribosomal complex in Plasmodium falciparum.

The Protein Phosphatase type 1 catalytic subunit (PP1c) (PF3D7_1414400) operates in combination with various regulatory proteins to specifically direct and control its phosphatase activity. However, little is known about this phosphatase and its regulators in the human malaria parasite, Plasmodium falciparum. To address this gap, we conducted a comprehensive investigation into structural and functional characteristics of a conserved Plasmodium-specific regulator called Gametocyte EXported Protein 15, GEXP15 (PF3D7_1031600). Through in silico analysis, we identified three significant regions of interest in GEXP15: an N-terminal region housing a PP1-interacting RVxF motif, a conserved domain whose function is unknown and a GYF-like motif that potentially facilitates specific protein-protein interactions. To further elucidate the role of GEXP15, we conducted in vitro interaction studies, which demonstrated a direct interaction between GEXP15 and PP1 via the RVxF binding motif. This interaction was found to enhance phosphatase activity of PP1. Additionally, utilizing a transgenic GEXP15-tagged line and live microscopy, we observed high expression of GEXP15 in late asexual stages of the parasite, with localization predominantly in the parasite nucleus. Immunoprecipitation assays followed by mass spectrometry analyses revealed GEXP15s interaction with ribosomal and RNA binding proteins. Furthermore, through pulldown analyses of recombinant functional domains of GEXP15 tagged with a His-tag, we confirmed its binding to the ribosomal complex via the GYF domain. Collectively, our study sheds light on the PfGEXP15-PP1-ribosome interaction, which plays a crucial role in protein translation. These findings suggest that PfGEXP15 could serve as a potential target for the development of malaria drugs.

microbiology↗

bioRxiv2019

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that Dara regimens decrease the frequency of total NK cells. Here we show that, despite this reduction, NK cells play a pivotal role in Dara anti-MM activity. CD38 on NK cells is essential for Dara-induced immune modulation, and its expression is restricted to NK cells with effector function. We also show that Dara induces rapid CD38 protein degradation associated with NK cell activation, leaving an activated CD38-negative NK cell population. CD38+ NK cell targeting by Dara also promotes monocyte activation, inducing an increase in T cell costimulatory molecules (CD86/80) and enhancing anti-MM phagocytosis activity ex-vivo and in vivo. In support of Daras immunomodulating role, we show that MM patients that discontinued Dara therapy because of progression maintain targetable unmutated surface CD38 expression on their MM cells, but retain effector cells with impaired cellular immune function. In summary, we report that CD38+ NK cells may be an unexplored therapeutic target for priming the immune system of MM patients.

cancer biology↗

bioRxiv2019

Rab11A regulates the constitutive secretory pathway during Toxoplasma gondii invasion of host cells and parasite replication.

Toxoplasma gondii possesses an armada of secreted virulent factors that enable parasite invasion and survival into host cells. These factors are contained in specific secretory organelles, the rhoptries, micronemes and dense granules that release their content upon host cell recognition. Dense granules are secreted in a constitutive manner during parasite replication and play a crucial role in modulating host metabolic and immune responses. While the molecular mechanisms triggering rhoptry and microneme release upon host cell adhesion have been well studied, constitutive secretion remains a poorly explored aspect of T. gondii vesicular trafficking. Here, we investigated the role of the small GTPase Rab11A, a known regulator of exocytosis in eukaryotic cells. Our data revealed an essential role of Rab11A in promoting the cytoskeleton driven transport of DG and the release of their content into the vacuolar space. Rab11A also regulates transmembrane protein trafficking and localization during parasite replication, indicating a broader role of Rab11A in cargo exocytosis at the plasma membrane. Moreover, we found that Rab11A also regulates extracellular parasite motility and adhesion to host cells. In line with these findings, MIC2 secretion was altered in Rab11A-defective parasites, which also exhibited severe morphological defects. Strikingly, by live imaging we observed a polarized accumulation of Rab11A-positive vesicles and dense granules at the apical pole of extracellular motile parasites suggesting that a Rab11A-dependent apically polarized transport of cargo regulates parasite motility.

microbiology↗